Adipotide (FTPP) Research: Prohibitin-Targeting Peptide Mechanism and Preclinical Evidence

Adipotide, also called FTPP or prohibitin-targeting peptide 1, is an experimental proapoptotic peptidomimetic studied for its ability to selectively destroy the blood vessels that supply white adipose tissue. In preclinical adipotide research it homes to prohibitin on fat-tissue vasculature, triggers apoptosis of those endothelial cells, and starves the surrounding fat cells of their blood supply. This vascular-ablation mechanism sets it apart from every appetite or metabolic peptide currently studied, and it remains a research-only compound with no approved human use.

The compound occupies an unusual position in the peptide literature. Most metabolic peptides under investigation act on receptors that regulate appetite, insulin signaling, or energy expenditure. Adipotide does none of these things directly. Instead it exploits a vascular address system, using a targeting sequence discovered through phage display to deliver a cell-killing payload specifically to the microvasculature of white fat. Understanding how that two-part design works, and what the animal data actually show, is essential for anyone evaluating this molecule in a laboratory context.

What Adipotide Is

Adipotide is a chimeric peptide with the sequence CKGGRAKDC-GG-D(KLAKLAK)2. It has two functional halves joined by a short glycine linker. The first half, CKGGRAKDC, is a cyclic nine-amino-acid homing peptide that binds prohibitin, a protein expressed on the surface of endothelial cells lining white adipose tissue vessels. The second half, D(KLAKLAK)2, is a synthetic proapoptotic motif built from D-amino acids. On its own this KLAKLAK sequence is relatively inert to mammalian cells because it cannot cross the plasma membrane, but once the homing peptide delivers it inside a target cell it disrupts mitochondrial membranes and initiates programmed cell death.

The molecule was developed at the University of Texas MD Anderson Cancer Center by a team led by Mikhail Kolonin and Wadih Arap. Its formal designation is prohibitin-targeting peptide 1, sometimes abbreviated prohibitin-TP01. The use of D-amino acids in the killing domain is a deliberate stability choice, since D-configuration residues resist proteolytic degradation and extend the functional half-life of the payload in circulation, a principle discussed in broader work on peptide stability and modification.

Mechanism of Action: Targeting the Fat Vasculature

The conceptual foundation of adipotide comes from the observation that adipose tissue, like a tumor, depends on an extensive and dynamic blood supply to expand. White fat cannot grow without angiogenesis, and the endothelial cells feeding that fat express distinct surface markers. Adipotide research is built on the idea that if you can ablate the vasculature, the tissue it supports will regress.

The homing sequence CKGGRAKDC recognizes prohibitin displayed on white adipose endothelium. Prohibitin is normally a mitochondrial and nuclear protein, but in fat vasculature it is presented at the cell surface, where it functions as a vascular zip code. When the homing peptide binds prohibitin, the attached D(KLAKLAK)2 domain is internalized and localizes to mitochondria, where it triggers membrane depolarization and caspase-dependent apoptosis. The endothelial cells die, the capillary network supplying the fat depot collapses, and the adipocytes that depended on that perfusion undergo their own resorption over the following days.

This is a fundamentally different strategy from receptor agonism. A GLP-1 style compound such as the triple agonist studied in retatrutide research works by signaling satiety and altering nutrient handling. Adipotide bypasses signaling entirely and removes the anatomical infrastructure of the fat depot. That mechanistic contrast is one of the reasons the compound continues to draw attention in comparative metabolic research.

Preclinical Evidence in Rodent Models

The foundational study appeared in Nature Medicine in 2004. Kolonin and colleagues published “Reversal of obesity by targeted ablation of adipose tissue,” describing how in vivo phage display was used to screen billions of random peptide sequences for ones that would home to white fat vasculature. The sequence CKGGRAKDC emerged repeatedly, and the team identified prohibitin as its binding partner, establishing the protein as a vascular marker of white fat. When the homing peptide was fused to the D(KLAKLAK)2 proapoptotic motif and administered to obese mice for roughly four weeks, the treated animals showed approximately a 30 percent reduction in body weight compared with controls, driven by loss of fat mass rather than lean tissue.

That first paper mattered because it validated the entire vascular-targeting premise in a living metabolic system. The weight reduction tracked with resorption of adipose depots, and the effect required both halves of the molecule. Neither the homing peptide alone nor the killing peptide alone produced the same result, confirming that targeted delivery was doing the work rather than nonspecific toxicity.

Primate Study Data

The most cited adipotide research is the 2011 Science Translational Medicine paper by Barnhart and colleagues, titled “A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys.” Rhesus monkeys are a far more physiologically relevant model than rodents for human metabolic questions, which made this study a significant step. Spontaneously obese monkeys received the compound over a 28-day treatment window, and the treated animals lost an average of approximately 11 percent of their body weight, while saline controls showed no meaningful change over the same period.

The researchers used MRI and DEXA imaging to characterize what was lost, and the reductions appeared in both subcutaneous and visceral adipose tissue rather than in muscle or bone. Alongside the weight loss, the monkeys showed improved insulin sensitivity, consistent with the general finding that reducing visceral fat mass improves glucose handling. The magnitude of the effect in a primate model is what cemented adipotide as a reference compound in the vascular-ablation approach to metabolic research.

The same study surfaced the compound’s central liability. Treated animals developed reversible renal changes, including elevated serum creatinine and structural signs of renal tubular injury. The toxicity resolved after treatment stopped, but its appearance in the primate model is the reason the compound has not moved smoothly toward broad clinical development. Prohibitin is not exclusively expressed on fat vasculature, and the kidney appears to be a site of off-target accumulation. Any honest summary of adipotide research has to hold the efficacy data and the nephrotoxicity signal together, because both come from the same landmark experiment.

Key Research Findings

• Sequence CKGGRAKDC-GG-D(KLAKLAK)2: a cyclic prohibitin-homing peptide fused to a D-amino-acid proapoptotic motif via a glycine linker.
• Kolonin et al., Nature Medicine 2004: obese mice treated for approximately 28 days showed roughly a 30 percent body weight reduction driven by fat-mass loss.
• Barnhart et al., Science Translational Medicine 2011: obese rhesus monkeys lost an average of approximately 11 percent body weight over 28 days versus no change in saline controls.
• Fat loss in the primate study spanned both subcutaneous and visceral depots, confirmed by MRI and DEXA, and was accompanied by improved insulin sensitivity.
• Reversible renal tubular toxicity, including elevated creatinine, was the principal dose-limiting finding in the primate study.
• Mechanism is vascular ablation rather than receptor agonism, distinguishing it from incretin and appetite-modulating peptides.

Why Analytical Verification Matters for This Compound

Adipotide is a comparatively complex synthetic peptide. The cyclic disulfide constraint on the homing domain and the D-amino-acid content of the killing domain both create synthesis and purity challenges that a simple linear peptide does not present. Incomplete cyclization, incorrect stereochemistry, or truncated sequences can all compromise whether a research sample behaves the way the published literature describes. For a molecule whose entire function depends on precise targeting, identity and purity data are not optional.

This is why any research-grade material should be accompanied by a batch-specific certificate of analysis. Mass spectrometry confirms the molecular identity and can flag truncation or racemization products, while high-performance liquid chromatography quantifies purity against known impurities. Maple Research Labs publishes independent third-party analytical data through its certificates of analysis so that researchers can verify what they are working with before designing an experiment. You can review the full research catalog on the peptides page, and compare handling considerations against other well-characterized compounds such as those covered in GHK-Cu research.

Where Adipotide Sits in the Research Landscape

Adipotide is best understood as a proof-of-concept molecule rather than a finished therapeutic candidate. It demonstrated that vascular targeting can drive selective fat resorption in two species, and it did so through a mechanism that no receptor-based compound replicates. At the same time, its renal toxicity profile keeps it firmly in the research-tool category, useful for interrogating adipose vascular biology and prohibitin display rather than as a template for direct human application. Researchers comparing metabolic strategies often set it against enzyme-inhibition approaches such as the NNMT pathway explored in 5-Amino-1MQ research, since the two illustrate opposite ends of the mechanistic spectrum, one removing tissue and the other reprogramming its metabolism.

The prohibitin-targeting concept has also seeded follow-on work in tumor vasculature and targeted drug delivery, since the same address-and-payload logic generalizes beyond fat. For the peptide research community, adipotide remains a clear example of how a homing sequence identified by phage display can be weaponized against a specific tissue, and of why rigorous preclinical safety characterization is inseparable from any efficacy claim.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. All information above summarizes published in-vitro and animal-model findings and does not describe or recommend human administration.